Results 41 to 50 of about 5,903 (227)

Folinic Acid Enhanced Cytotoxicity of Fluoropyrimidines In Human Breast Cancer Cells

Pteridines, 1993
This report describes the effects of the natural diastereoisomer of 5-formyltetrahydrofolate (6S)- and of the mixture of both the natural and unnatural diastereoisomers (6RS)-5-HCO-H4PteGlu (folinate) on the cytotoxicity of 5-fluoro-2′-deoxyuridine ...
Mandelbaum-Shavit Frederika
doaj   +1 more source

Systemic therapy for colorectal cancer [PDF]

Archive of Oncology, 2003
Colorectal cancer alone accounts for around 200,000 deaths in Europe and represents a significant health problem. Although about fifty percent of patients are cured by surgery alone, the other half will eventually die due to metastatic disease, which ...
Štabuc Borut
doaj   +1 more source

Toxic and Adverse Effects of Chemotherapy with 5-Fluoropyrimidine Drugs. Could Dihydropyrimidine Dehydrogenase Enzyme Screening Serve as a Prerequisite to Successful Chemotherapy? [PDF]

Journal of Biomedical & Clinical Research, 2020
The article presents a detailed survey of recent publications in the literature concerning clinical expertise, existing guidelines, and differing opinions on Fluoropyrimidine chemotherapy-related toxicity and the implication of Dihydropyrimidine ...
Velko Minchev
doaj   +3 more sources

Age‐Dependent Prognostic Significance of Preoperative Transthyretin After Curative Resection for Stage I–III Colorectal Cancer

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Background Preoperative malnutrition and systemic inflammation are established determinants of adverse outcomes in colorectal cancer (CRC). Transthyretin (TTR), a rapid‐turnover hepatic protein, reflects both nutritional and inflammatory status; however, its clinical utility may be influenced by age‐ and sex‐related variability.
Ayane Kawata, Yuji Miyamoto, Hiro Nakamura, Takahiko Akiyama, Kota Arima, Katsuhiro Ogawa, Yukiharu Hiyoshi, Masaaki Iwatsuki   +7 more
wiley   +1 more source

Germline pharmacogenomics of thymidylate synthase gene in patients with gastrointestinal malignancies treated with fluoropyrimidines-based chemotherapy regimens

, 2019
545 Background: Fluoropyrimidines are antimetabolites that target the S phase of the cell cycle. The active metabolite, 5-fluorodeoxyuridine monophosphate inhibits thymidylate synthase (TS) enzyme, thus preventing DNA synthesis and ultimately cell death.
Patel, Girijesh K, Grimm, Leander, Wang, Bin, Hunter, John, Nelson, Cindy, Hosein, Peter Joel, Frankel, Arthur E, Singh Maharjan, Anu, Rider, Paul, Khushman, Moh'd M, Awan, Saad, Taylor, William R, Pai, Sachin, Smith, Clayton, Liles, Spencer, McMillin, Gwendolyn A, Singh, Ajay   +16 more
core   +1 more source

One‐Year Changes in Frailty Components After Curative Minimally Invasive Surgery for Colorectal Cancer in Older Patients

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Background Frailty predicts outcomes after colorectal cancer surgery, but postoperative changes remain unclear. We previously reported improvement in FRAIL Scale‐based frail/pre‐frail status 1 year after curative minimally invasive surgery (MIS).
Hajime Ushigome, Takuya Suzuki, Shunsuke Hayakawa, Akira Kato, Yushi Yamakawa, Kenta Saito, Hiroyuki Sagawa, Ryo Ogawa, Hiroki Takahashi, Shuji Takiguchi   +9 more
wiley   +1 more source

Oncology Specialists' Perceptions and Insights Into Dihydropyrimidine Dehydrogenase Testing in Palestine

Cancer Reports
Background This study evaluated awareness, prevalence, and utilization of dihydropyrimidine dehydrogenase (DPD) testing and pharmacogenomics among oncologists, residents, and clinical pharmacists working in Palestinian hospitals.
Mohammad Dweib, Hussein Hallak, Hani Hour, Asmahan Alzeer, Raya Fatafta, Leen Albaw   +5 more
doaj   +1 more source

Can Chemoradiotherapy Expand Immune Checkpoint Blockade Responsiveness in Mismatch Repair‐Proficient Rectal Cancer?

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Immune checkpoint blockade (ICB) has transformed the treatment of mismatch repair‐deficient (dMMR) colorectal cancer but produces no meaningful benefit in advanced mismatch repair‐proficient (pMMR) disease. In the neoadjuvant setting, however, pathological responses have been reported in a subset of pMMR tumors, suggesting that clinical ...
Kimihiro Yamashita, Takeru Matsuda, Junko Mukohyama, Ryohei Sasaki, Yoshihiro Kakeji   +4 more
wiley   +1 more source

The Frequency of DPYD c.557A>G in the Dominican Population and Its Association with African Ancestry

Pharmaceutics
Background/Objectives: Genetic polymorphism of the dihydropyrimidine dehydrogenase gene (DPYD) is responsible for the variability found in the metabolism of fluoropyrimidines such as 5-fluorouracil (5-FU), capecitabine, or tegafur.
Mariela Guevara, Carla González de la Cruz, Fernanda Rodrigues-Soares, Ernesto Rodríguez, Caíque Manóchio, Eva Peñas-Lledó, Pedro Dorado, Adrián LLerena   +7 more
doaj   +1 more source

Cost‐effectiveness of DPYD genotyping prior to fluoropyrimidine‐based treatment for colorectal cancer in Wales

British Journal of Clinical Pharmacology, EarlyView.
Abstract Background Regulatory guidance in the United Kingdom advises DPYD genotyping prior to fluoropyrimidine‐based treatment. This economic evaluation estimated the costs and outcomes associated with DPYD screening prior to prescribing fluoropyrimidines for colorectal cancer in Wales and also considers additional variants to those included in ...
Catrin O. Plumpton, Sian M. Morgan, Richard A. Adams, Samantha Cox, Angharad A. Rudkin, Megan Fealey, Craig Barrington, Michelle D. Wood, Dyfrig A. Hughes   +8 more
wiley   +1 more source